Ishita Drugs & Industries Ltd
₹ 89.0
3.44%
26 Nov
4:00 p.m.
About
Incorporated in 1992, Ishita Drugs & Industries Limited is the flagship company of ISHITA group. It is engaged in manufacture of various Active Pharma Ingredients, drug intermediates, fine chemicals and excipients.
Key Points
- Market Cap ₹ 26.6 Cr.
- Current Price ₹ 89.0
- High / Low ₹ 105 / 56.0
- Stock P/E 36.0
- Book Value ₹ 34.3
- Dividend Yield 0.00 %
- ROCE 10.8 %
- ROE 7.86 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 28.4 to 16.8 days.
Cons
- Stock is trading at 2.58 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 10.8% over past five years.
- Company has a low return on equity of 8.00% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.76 | 7.34 | 7.54 | 7.10 | 6.44 | 6.90 | 9.09 | 14.83 | 13.95 | 14.09 | 12.07 | 15.19 | 14.01 | |
| 11.22 | 6.89 | 7.23 | 6.82 | 6.08 | 6.45 | 8.57 | 14.07 | 13.03 | 13.01 | 11.31 | 14.28 | 13.08 | |
| Operating Profit | 0.54 | 0.45 | 0.31 | 0.28 | 0.36 | 0.45 | 0.52 | 0.76 | 0.92 | 1.08 | 0.76 | 0.91 | 0.93 |
| OPM % | 4.59% | 6.13% | 4.11% | 3.94% | 5.59% | 6.52% | 5.72% | 5.12% | 6.59% | 7.67% | 6.30% | 5.99% | 6.64% |
| 0.19 | 0.00 | 0.17 | 0.13 | 0.08 | 0.12 | 0.16 | 0.16 | 0.31 | 0.11 | 0.20 | 0.28 | 0.22 | |
| Interest | 0.03 | 0.03 | 0.04 | 0.06 | 0.04 | 0.11 | 0.06 | 0.03 | 0.03 | 0.02 | 0.05 | 0.09 | 0.07 |
| Depreciation | 0.09 | 0.12 | 0.15 | 0.15 | 0.14 | 0.14 | 0.16 | 0.18 | 0.15 | 0.13 | 0.13 | 0.11 | 0.10 |
| Profit before tax | 0.61 | 0.30 | 0.29 | 0.20 | 0.26 | 0.32 | 0.46 | 0.71 | 1.05 | 1.04 | 0.78 | 0.99 | 0.98 |
| Tax % | 32.79% | 33.33% | 24.14% | 30.00% | 30.77% | 25.00% | 26.09% | 23.94% | 20.95% | 23.08% | 25.64% | 24.24% | |
| 0.42 | 0.20 | 0.22 | 0.14 | 0.18 | 0.25 | 0.35 | 0.55 | 0.83 | 0.80 | 0.58 | 0.75 | 0.74 | |
| EPS in Rs | 1.40 | 0.67 | 0.74 | 0.47 | 0.60 | 0.84 | 1.17 | 1.84 | 2.78 | 2.68 | 1.94 | 2.51 | 2.48 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 11% |
| 3 Years: | 3% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 16% |
| 3 Years: | -3% |
| TTM: | 14% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 47% |
| 3 Years: | 27% |
| 1 Year: | 24% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 9% |
| 3 Years: | 8% |
| Last Year: | 8% |
Balance Sheet
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 |
| Reserves | 2.08 | 2.28 | 2.50 | 2.64 | 2.82 | 3.07 | 3.42 | 3.97 | 4.80 | 5.61 | 6.18 | 6.93 | 7.27 |
| 0.19 | 0.19 | 0.09 | 1.13 | 0.01 | 0.13 | 0.20 | 0.29 | 0.04 | 0.00 | 0.96 | 0.00 | 2.11 | |
| 2.73 | 1.15 | 1.37 | 1.43 | 1.37 | 0.97 | 1.73 | 2.30 | 1.43 | 2.66 | 1.27 | 0.89 | 2.58 | |
| Total Liabilities | 7.99 | 6.61 | 6.95 | 8.19 | 7.19 | 7.16 | 8.34 | 9.55 | 9.26 | 11.26 | 11.40 | 10.81 | 14.95 |
| 1.17 | 1.36 | 1.26 | 1.11 | 1.02 | 1.19 | 1.30 | 1.14 | 1.00 | 0.88 | 0.89 | 0.80 | 0.73 | |
| CWIP | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1.21 | 1.45 | 1.82 | 2.15 | 2.70 | 3.15 | 4.04 | 5.29 | 3.11 | 4.06 | 3.39 | 3.34 | 4.60 |
| 5.58 | 3.80 | 3.87 | 4.93 | 3.47 | 2.82 | 3.00 | 3.12 | 5.15 | 6.32 | 7.12 | 6.67 | 9.62 | |
| Total Assets | 7.99 | 6.61 | 6.95 | 8.19 | 7.19 | 7.16 | 8.34 | 9.55 | 9.26 | 11.26 | 11.40 | 10.81 | 14.95 |
Cash Flows
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.22 | 0.73 | 0.11 | 0.26 | 0.52 | 0.72 | 0.79 | 1.05 | -0.67 | 3.08 | -2.90 | 2.12 | |
| 0.22 | -0.45 | -0.34 | -0.28 | -0.55 | -0.69 | -1.06 | -1.15 | 2.45 | -0.93 | 0.59 | 0.13 | |
| 0.18 | 0.03 | -0.07 | 1.07 | -1.05 | 0.05 | 0.09 | 0.09 | -0.24 | 0.00 | 1.05 | -0.87 | |
| Net Cash Flow | 0.18 | 0.31 | -0.29 | 1.05 | -1.08 | 0.08 | -0.19 | -0.01 | 1.54 | 2.14 | -1.25 | 1.38 |
Ratios
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 87.84 | 52.21 | 60.51 | 96.65 | 96.35 | 43.38 | 47.38 | 32.24 | 39.77 | 13.99 | 54.43 | 16.82 |
| Inventory Days | 54.18 | 73.00 | 91.60 | 55.65 | 51.49 | 55.56 | 42.20 | 18.49 | 23.06 | 34.81 | 68.22 | 34.27 |
| Days Payable | 103.33 | 69.24 | 78.31 | 91.07 | 108.49 | 43.21 | 78.70 | 60.25 | 34.76 | 73.22 | 36.67 | 14.87 |
| Cash Conversion Cycle | 38.69 | 55.98 | 73.80 | 61.23 | 39.35 | 55.72 | 10.88 | -9.52 | 28.07 | -24.41 | 85.99 | 36.22 |
| Working Capital Days | 51.83 | 57.68 | 64.38 | 67.35 | 57.24 | 32.27 | 8.03 | -6.65 | 29.83 | -27.46 | 71.97 | 21.87 |
| ROCE % | 12.85% | 6.72% | 5.98% | 4.21% | 4.77% | 7.16% | 8.12% | 10.68% | 14.32% | 12.90% | 8.86% | 10.77% |
Documents
Announcements
-
Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations, 2011
2d - Disclosure of acquisition of 500 shares by promoter.
-
Announcement under Regulation 30 (LODR)-Change in Management
12 Nov - Approved financial results and resignation of director.
-
Outcome Of Board Meeting Held On 12Th November, 2024
12 Nov - Approved unaudited financial results and resignation of director.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 12Th November, 2024
12 Nov - Approved unaudited financial results and resignation of director.
-
Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of The SEBI (LODR) Regulations, 2015 For The Quarter Ended 30Th September, 2024
6 Nov - Board meeting to approve Q2 financial results.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Product Portfolio:[1]
a) Active Pharma Ingredients: Sulfa Drugs / Sulfonamides, Vitamins, Fluoro Quinolones, Antibiotics, Anthelmintics, Iodides & Citrates (Salts), Food Additives / Excipients, etc.
b) Drug Intermediates: Sulfonamido Phenyl, Chloro Phenyl, Hydroxy Methyl, Dimethyl Benzil, Phenyl Coumarin
c) Fine Chemicals: Salicylanilide, Para Bromo Toluene 99.5%, Pyridine Hydrobromide, Nicotinic Acid Hydrazide